Life Biosciences

Thesis

Life Biosciences received the first-ever FDA IND clearance for a cellular rejuvenation therapy (January 2026). ER-100 delivers three reprogramming transcription factors via intravitreal injection for optic neuropathies. Phase 1 trial initiated Q1 2026. Just closed $80M in financing (April 8, 2026). Co-founded by David Sinclair. This is a historically significant regulatory milestone. The first time the FDA has cleared an IND for cellular rejuvenation. While the initial application is narrow (optic neuropathies), the platform technology (reprogramming transcription factors) has much broader implications for aging and age-related disease. David Sinclair's involvement as co-founder adds both credibility and controversy. He is the most prominent longevity researcher but also attracts scientific skepticism. The $80M April 2026 financing provides fresh runway for the Phase 1 trial. The xenotransplantation categorization is approximate. Life Biosciences is more precisely in the cellular reprogramming/rejuvenation space. The company bridges longevity research and clinical development, with the FDA IND clearance representing the critical transition from research to regulated medicine.

Catalysts

• +First-ever FDA IND clearance for cellular rejuvenation therapy (January 2026)
• +$80M financing closed April 8, 2026. Fresh runway for Phase 1 trial
• +Platform technology could extend beyond optic neuropathies to broader aging applications

Risks

• -Phase 1 trial. Earliest stage of clinical development with uncertain outcomes
• -David Sinclair's controversial reputation may attract scientific skepticism
• -Cellular reprogramming in humans is unproven. Safety profile unknown

Common questions